Syngene International has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immuno-oncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library. Under the terms of the agreement, Syngene will screen target antigens against Zumutor’s proprietary human antibody libraries to identify and characterize novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programmes for its partners.
Commenting on the collaboration, Dr Manoj Nerurkar, Chief Operating Officer, Syngene International, said: “Syngene has been a pioneer in discovery research and we see discovery biology as one of our growth drivers. This partnership will expand our existing portfolio of therapeutic antibody discovery platforms for our clients.”